i*****x
发帖数: 1 | 1 请教肿瘤新抗原/个性化疫苗这个领域，的转化前景怎样？
非常感谢！ | f****6
发帖数: 365 | 2 有经验的牛人能否谈一谈？ 洗耳恭听！
【在 i*****x 的大作中提到】
: 请教肿瘤新抗原/个性化疫苗这个领域，的转化前景怎样？
: 非常感谢！
| l*********d
发帖数: 315 | 3 我老没啥neoantigen的经验，只做过beta cell auto antigen。
感觉上neoantigen不是问题重点，一旦触发antigen specific immunity，这个antigen
就不是很重要了。在beta cell这块，先是anti-GAD 和-Insulin, 等T cell杀红眼了，
啥antigen都可以recognize。
--------------------------------------------------------------------
再上点干货:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580128/
Antigen-Based Therapy with Glutamic Acid Decarboxylase (GAD) Vaccine in
Patients with Recent-Onset Type 1 Diabetes: A Randomised Double-Masked
Controlled Trial
Findings
The ratio (experimental to control) of the adjusted population mean of C-
peptide for the GAD-alum ×3 and GAD-alum ×2/alum ×1 groups is 0.998 (95%
CI: [0.779, 1.22], p = 0.98) and 0.926 (95% CI: [0.720, 1.13], p = 0.50),
respectively. HbA1c and insulin use did not differ between groups. There was
no difference in rate or severity of adverse events between groups.
Interpretation $$$
Antigen-based immunotherapy therapy using GAD-alum given subcutaneously in
two or three doses over 4 to 12 weeks does not alter the course of loss of
insulin secretion over one year in subjects with recently diagnosed T1DM.
While antigen-based therapy is a highly desireable treatment and is
effective in animal models, translation to human autoimmune disease remains
a challenge. |
|
